KR20160114794A - A cosmetic composition for skin improvement comprising bulb extract - Google Patents
A cosmetic composition for skin improvement comprising bulb extract Download PDFInfo
- Publication number
- KR20160114794A KR20160114794A KR1020150040919A KR20150040919A KR20160114794A KR 20160114794 A KR20160114794 A KR 20160114794A KR 1020150040919 A KR1020150040919 A KR 1020150040919A KR 20150040919 A KR20150040919 A KR 20150040919A KR 20160114794 A KR20160114794 A KR 20160114794A
- Authority
- KR
- South Korea
- Prior art keywords
- skin
- lily
- bulb extract
- extract
- bulb
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 141
- 239000000203 mixture Substances 0.000 title claims abstract description 112
- 239000002537 cosmetic Substances 0.000 title claims abstract description 34
- 230000006872 improvement Effects 0.000 title description 23
- 230000000694 effects Effects 0.000 claims abstract description 52
- 241000234435 Lilium Species 0.000 claims abstract description 43
- 230000003020 moisturizing effect Effects 0.000 claims abstract description 22
- 230000037303 wrinkles Effects 0.000 claims abstract description 18
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 16
- 230000037394 skin elasticity Effects 0.000 claims abstract description 15
- 206010040880 Skin irritation Diseases 0.000 claims abstract description 10
- 230000036556 skin irritation Effects 0.000 claims abstract description 10
- 231100000475 skin irritation Toxicity 0.000 claims abstract description 10
- 241000234479 Narcissus Species 0.000 claims abstract description 7
- 230000001603 reducing effect Effects 0.000 claims abstract description 5
- 241000755716 Convallaria Species 0.000 claims description 36
- 235000009046 Convallaria majalis Nutrition 0.000 claims description 36
- 238000000034 method Methods 0.000 claims description 15
- 206010013786 Dry skin Diseases 0.000 claims description 6
- 230000037336 dry skin Effects 0.000 claims description 6
- 238000004299 exfoliation Methods 0.000 claims description 4
- 230000002708 enhancing effect Effects 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 abstract description 7
- 108010076876 Keratins Proteins 0.000 abstract description 6
- 102000011782 Keratins Human genes 0.000 abstract description 6
- 230000014759 maintenance of location Effects 0.000 abstract description 2
- 229940062460 convallaria majalis bulb extract Drugs 0.000 abstract 2
- 239000012634 fragment Substances 0.000 abstract 2
- 206010048218 Xeroderma Diseases 0.000 abstract 1
- 206010021198 ichthyosis Diseases 0.000 abstract 1
- 239000006071 cream Substances 0.000 description 72
- 210000003491 skin Anatomy 0.000 description 61
- 238000002474 experimental method Methods 0.000 description 36
- 244000230712 Narcissus tazetta Species 0.000 description 25
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 23
- 239000006210 lotion Substances 0.000 description 17
- -1 polyoxyethylene Polymers 0.000 description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 13
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 11
- 230000001965 increasing effect Effects 0.000 description 10
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 239000003921 oil Substances 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 241000196324 Embryophyta Species 0.000 description 8
- 235000019198 oils Nutrition 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- 230000002500 effect on skin Effects 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 6
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 6
- 239000000839 emulsion Substances 0.000 description 6
- 230000036620 skin dryness Effects 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 210000004207 dermis Anatomy 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 238000005194 fractionation Methods 0.000 description 5
- 235000011187 glycerol Nutrition 0.000 description 5
- 239000000049 pigment Substances 0.000 description 5
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000007921 spray Substances 0.000 description 4
- 210000000434 stratum corneum Anatomy 0.000 description 4
- 239000000454 talc Substances 0.000 description 4
- 229910052623 talc Inorganic materials 0.000 description 4
- 235000012222 talc Nutrition 0.000 description 4
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 244000178870 Lavandula angustifolia Species 0.000 description 3
- 235000010663 Lavandula angustifolia Nutrition 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 230000001747 exhibiting effect Effects 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 230000036074 healthy skin Effects 0.000 description 3
- 210000002510 keratinocyte Anatomy 0.000 description 3
- 239000001102 lavandula vera Substances 0.000 description 3
- 235000018219 lavender Nutrition 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 230000008591 skin barrier function Effects 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 235000015112 vegetable and seed oil Nutrition 0.000 description 3
- 239000008158 vegetable oil Substances 0.000 description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 2
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 2
- 229940058015 1,3-butylene glycol Drugs 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- 239000004386 Erythritol Substances 0.000 description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 2
- 239000004606 Fillers/Extenders Substances 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 244000223141 Leucojum aestivum Species 0.000 description 2
- 241001648859 Lilium candidum Species 0.000 description 2
- 239000004909 Moisturizer Substances 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000011449 brick Substances 0.000 description 2
- 235000019437 butane-1,3-diol Nutrition 0.000 description 2
- 235000014121 butter Nutrition 0.000 description 2
- 239000000378 calcium silicate Substances 0.000 description 2
- 229910052918 calcium silicate Inorganic materials 0.000 description 2
- 235000012241 calcium silicate Nutrition 0.000 description 2
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 2
- 235000019414 erythritol Nutrition 0.000 description 2
- 229940009714 erythritol Drugs 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 229920002674 hyaluronan Polymers 0.000 description 2
- 229960003160 hyaluronic acid Drugs 0.000 description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 150000002632 lipids Chemical group 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000001333 moisturizer Effects 0.000 description 2
- 239000004570 mortar (masonry) Substances 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 230000009759 skin aging Effects 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical class CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 1
- TYYHDKOVFSVWON-UHFFFAOYSA-N 2-butyl-2-methoxy-1,3-diphenylpropane-1,3-dione Chemical compound C=1C=CC=CC=1C(=O)C(OC)(CCCC)C(=O)C1=CC=CC=C1 TYYHDKOVFSVWON-UHFFFAOYSA-N 0.000 description 1
- YLZOPXRUQYQQID-UHFFFAOYSA-N 3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]propan-1-one Chemical compound N1N=NC=2CN(CCC=21)CCC(=O)N1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F YLZOPXRUQYQQID-UHFFFAOYSA-N 0.000 description 1
- 150000005168 4-hydroxybenzoic acids Chemical class 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 1
- QCYFYNAOZQVNBI-UHFFFAOYSA-M C[SiH2]O.C(C(O)C)(=O)[O-].[Na+] Chemical compound C[SiH2]O.C(C(O)C)(=O)[O-].[Na+] QCYFYNAOZQVNBI-UHFFFAOYSA-M 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 208000035874 Excoriation Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 241000208680 Hamamelis mollis Species 0.000 description 1
- 208000007514 Herpes zoster Diseases 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 229920000161 Locust bean gum Polymers 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 description 1
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- YBGZDTIWKVFICR-JLHYYAGUSA-N Octyl 4-methoxycinnamic acid Chemical compound CCCCC(CC)COC(=O)\C=C\C1=CC=C(OC)C=C1 YBGZDTIWKVFICR-JLHYYAGUSA-N 0.000 description 1
- 241000233855 Orchidaceae Species 0.000 description 1
- 201000005702 Pertussis Diseases 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- ULUAUXLGCMPNKK-UHFFFAOYSA-N Sulfobutanedioic acid Chemical compound OC(=O)CC(C(O)=O)S(O)(=O)=O ULUAUXLGCMPNKK-UHFFFAOYSA-N 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- WGLPBDUCMAPZCE-UHFFFAOYSA-N Trioxochromium Chemical compound O=[Cr](=O)=O WGLPBDUCMAPZCE-UHFFFAOYSA-N 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 229940063655 aluminum stearate Drugs 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 229960005193 avobenzone Drugs 0.000 description 1
- IRERQBUNZFJFGC-UHFFFAOYSA-L azure blue Chemical compound [Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Al+3].[Al+3].[Al+3].[Al+3].[Al+3].[Al+3].[S-]S[S-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-] IRERQBUNZFJFGC-UHFFFAOYSA-L 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 229940078456 calcium stearate Drugs 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000004204 candelilla wax Substances 0.000 description 1
- 229940073532 candelilla wax Drugs 0.000 description 1
- 235000013868 candelilla wax Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 239000004203 carnauba wax Substances 0.000 description 1
- 235000013869 carnauba wax Nutrition 0.000 description 1
- 229940082483 carnauba wax Drugs 0.000 description 1
- 229940106189 ceramide Drugs 0.000 description 1
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229940107161 cholesterol Drugs 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229910000423 chromium oxide Inorganic materials 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- IUJAMGNYPWYUPM-UHFFFAOYSA-N hentriacontane Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC IUJAMGNYPWYUPM-UHFFFAOYSA-N 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 229940071826 hydroxyethyl cellulose Drugs 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical class C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- ZCTXEAQXZGPWFG-UHFFFAOYSA-N imidurea Chemical compound O=C1NC(=O)N(CO)C1NC(=O)NCNC(=O)NC1C(=O)NC(=O)N1CO ZCTXEAQXZGPWFG-UHFFFAOYSA-N 0.000 description 1
- WTFXARWRTYJXII-UHFFFAOYSA-N iron(2+);iron(3+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[O-2].[Fe+2].[Fe+3].[Fe+3] WTFXARWRTYJXII-UHFFFAOYSA-N 0.000 description 1
- SZVJSHCCFOBDDC-UHFFFAOYSA-N iron(II,III) oxide Inorganic materials O=[Fe]O[Fe]O[Fe]=O SZVJSHCCFOBDDC-UHFFFAOYSA-N 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 230000003780 keratinization Effects 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010420 locust bean gum Nutrition 0.000 description 1
- 239000000711 locust bean gum Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 239000010445 mica Substances 0.000 description 1
- 229910052618 mica group Inorganic materials 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 235000013379 molasses Nutrition 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 1
- 239000012454 non-polar solvent Substances 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 229960001679 octinoxate Drugs 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 208000028169 periodontal disease Diseases 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 229940071089 sarcosinate Drugs 0.000 description 1
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 1
- 210000001732 sebaceous gland Anatomy 0.000 description 1
- 210000002374 sebum Anatomy 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 239000002884 skin cream Substances 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 229940012831 stearyl alcohol Drugs 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 210000004003 subcutaneous fat Anatomy 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 210000000106 sweat gland Anatomy 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 239000006097 ultraviolet radiation absorber Substances 0.000 description 1
- 230000017260 vegetative to reproductive phase transition of meristem Effects 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 229940118846 witch hazel Drugs 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1
- 229940057977 zinc stearate Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9794—Liliopsida [monocotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/007—Preparations for dry skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/318—Foods, ingredients or supplements having a functional effect on health having an effect on skin health and hair or coat
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Botany (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Birds (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
- Cosmetics (AREA)
Abstract
Description
본 발명은 구근추출물을 포함하는 피부 개선용 조성물에 관한 것으로서, 보다 구체적으로 본 발명은 수선화구근추출물, 백합구근추출물, 은방울꽃구근추출물 또는 상기 각 추출물의 분획물을 유효성분으로 포함하는 피부 보습용 화장료 조성물, 피부 탄력성 증가 또는 주름개선용 화장료 조성물 및 피부건조증 예방 또는 치료용 약학 조성물에 관한 것이다.
The present invention relates to a composition for skin improvement comprising a bulbous extract. More particularly, the present invention relates to a composition for skin moisturizing comprising a solution of a bulbous bulb, a lily bulb extract, a lily of the valley bulb or a fraction thereof, A cosmetic composition for improving skin elasticity or wrinkle, and a pharmaceutical composition for preventing or treating dry skin.
피부는 크게 표피와 진피, 피하지방조직의 3개층으로 이루어져있으며, 외부 환경으로부터 인체를 보호하는 역할을 한다. 그 중 표피는 각질층, 과립층, 유극층, 기저층의 순서로 구분되는데 가장 최외각층인 각질층(Stratum Corneum)은 브릭 앤 모르타르(Brick and mortar)구조로 이루어져있다. 각질 세포들은 벽돌 역할을 하고 있고, 세포간 지질들은 벽돌인 각질 세포들을 단단하게 잡아주는 모르타르 역할을 함으로써 피부장벽을 형성하는 구조로 이러한 피부장벽은 체외로의 수분 증발을 억제하는 한편, 외부의 물리적이거나 화학적인 자극으로부터 인체를 보호한다. The skin is largely composed of three layers of epidermis, dermis and subcutaneous fat tissue, and protects the human body from external environment. Among them, the epidermis is divided into the stratum corneum, the granular layer, the polar layer, and the basal layer. The stratum corneum, which is the outermost layer, consists of a brick and mortar structure. The keratinocytes act as a brick, and the intercellular lipids form a skin barrier by acting as a mortar that firmly holds the bristle keratinocytes. Such a skin barrier inhibits the evaporation of water to the outside of the body, Or protects the body from chemical stimuli.
또한 각질층에는 수분 보유 능력이 있는 친수성의 천연 보습 인자(Natural Moisturizing Factor)라는 물질이 존재하여 피부 보습에 기여하고 있으며 피지선에서 나온 피지들과 땀샘에서 분비되는 땀으로 형성되는 적절한 유분은 피부의 수분 손실을 최소화 시켜 피부 보습을 유지한다.In addition, the stratum corneum has a hydrophilic natural moisturizing factor, which is capable of retaining moisture, contributes to moisturizing the skin. Appropriate oil, which is formed by sebum secreted from sebaceous glands and sweat glands, To minimize skin moisturization.
정상적인 각질세포층의 수분 함유량은 10 ~ 20 %로 수분 함유량이 10 % 이내가 되면 피부는 건조해지고 보호기능을 잃게 되어 노화 현상이 나타나기 때문에 각질층의 보습을 유지하는 것은 건강한 피부를 유지하는데 필수적이다.Maintaining the moisturization of the stratum corneum is essential for maintaining a healthy skin, as the normal keratinocyte layer has a moisture content of 10 to 20%, and when the moisture content is within 10%, the skin becomes dry and loses protection and aging.
그러나, 보습이 잘 유지되어 있는 건강한 피부라 하더라도 현대사회의 환경오염으로 인한 스트레스 혹은 바람, 혹한, 자외선 등의 혹독한 외부환경의 변화, 냉/난방과 같은 온도조절과 같은 사회 생활에서 오는 변화, 연령 증가로 인한 자연적인 노화, 화장 습관에 따른 피부 스트레스 등 여러 가지 요인들로 인하여 각질층의 피부장벽이 약해지고 보습이 감소하여 피부가 건조해지고 푸석해지며 거칠어지는 등의 현상이 나타나기 때문에 피부 보습제는 필수불가결한 요소가 되었다. 또한 피부 당김을 개선하고 보습력을 높이면서 피부의 진피 치밀도를 높여 더욱 건강한 피부를 구현하고자 하는 연구가 활발하게 진행되고 있다. 예를 들어, 한국공개특허 제1999-0070313호에는 지질 베이스인 폴리옥시에틸렌글리콜소야스테롤, 피토스테롤, 콜레스테롤, 레시틴, 세라마이드, 디이에이세틸포스페이트, 글리세린, 소듐락테이트메칠실라놀, 꿀 추출물, 히아루론산, 탄수화물복합체, 마치현 추출물 및 당밀 추출물을 함유하는 높은 보습효과를 나타내는 화장용 조성물이 개시되어 있고, 한국공개특허 제2002-0009939호에는 에리스리톨 또는 베타인을 포함하는 보습성이 개선된 실리콘유중수형 에멀젼 제형의 메이크-업용 화장료 조성물이 개시되어 있다. 그러나, 이들 화장료 조성물은 이에 포함된 화학적 성분으로 인하여, 사람의 피부에 따라 부작용을 나타내거나 또는 피부 보습력이 향상되지 않는 부작용이 있어, 부작용이 없는 보습용 화장료 조성물의 개발이 요구되고 있는 실정이다.However, even healthy skin with well-maintained moisturizing effects can be affected by environmental pollution in modern society, changes in harsh external environments such as wind, cold, ultraviolet rays, changes in social life such as temperature control such as cold / Skin aging due to increase in skin aging, and skin stress due to makeup habits, skin barrier is weakened, moisturizing is reduced, skin becomes dry, rough and rough, and so on, skin moisturizer is indispensable It became one factor. In addition, studies have been actively carried out to improve the pulling of the skin and improve the moisturizing power while increasing the density of the dermis of the skin to realize more healthy skin. For example, Korean Patent Laid-Open Publication No. 1999-0070313 discloses a liposomal composition comprising a lipid base such as polyoxyethylene glycol soya sterol, phytosterol, cholesterol, lecithin, ceramide, diaicetylphosphate, glycerin, sodium lactate methylsilanol, Carbohydrate complex, hyaluronic acid extract, and molasses extract, and Korean Patent Publication No. 2002-0009939 discloses a cosmetic composition containing a water-in-oil type silicone oil emulsion containing erythritol or betaine Of a cosmetic composition for make-up is disclosed. However, due to the chemical components contained in these cosmetic compositions, it is required to develop a cosmetic composition for moisturizing without adverse effects, because side effects are exhibited depending on human skin or side effects are not improved.
통상적으로, 식물은 추위나 건조와 같이 생장에 불리한 환경에 놓이게 되면 여러 가지 방법으로 삶을 이어나가기 위해 다양한 방법을 사용한다. 잎을 떨어뜨리거나, 휴면하거나, 씨앗로 지내거나, 구근 형태로 휴면한다. 상기 구근은 혹독한 조건에서 살아남기 위해 양분과 수분을 저장하기 위해 특별히 비대된 모습으로 발달된 식물의 특이적인 구조로서, 이들 구근에는 특이적인 다당체가 대량으로 함유되어 있다고 알려져 있다. 지금까지 다양한 천연식물로부터 유래된 추출물을 포함하는 기능성 화장품이 개발되어 왔으나, 식물의 구근을 주요성분으로 포함하는 기능성 화장품은 개발되지 않고 있다.
Typically, plants use a variety of methods to survive in a variety of ways once they are in an adverse environment, such as cold or dry. Leaves fall, dormant, seeded, or dormant in bulbous form. These bulbs are known to contain a large amount of specific polysaccharides in their bulbs, which are specific structures of plants developed to be particularly hypertrophied to store nutrients and moisture to survive harsh conditions. Functional cosmetics containing extracts derived from various natural plants have been developed, but functional cosmetics containing plant bulbs as main components have not been developed.
이러한 배경하에서, 부작용이 없이 피부 보습능, 각질 등을 비롯한 다양한 피부의 상태를 개선시킬 수 있는 기능성 화장품을 개발하기 위하여, 부작용을 최소화 할 수 있는 천연물을 대상으로 예의 연구노력한 결과, 수선화구근추출물, 백합구근추출물 또는 은방울꽃구근추출물이 수분 보유능, 각질, 피부자극, 피부 탄력성, 주름 등의 다양한 관점에서 피부상태를 개선시킬 수 있고, 이들을 조합하여 사용하면 상기 개선효과를 현저하게 증가시킬 수 있음을 확인하고, 본 발명을 완성하였다.
Under these circumstances, in order to develop functional cosmetics capable of improving various skin conditions including skin moisturizing ability, keratin and the like without side effects, it has been tried to study natural products which can minimize side effects, and as a result, It has been confirmed that the lily bulb extract or lily of the valley bulb extract can improve the skin condition from various viewpoints such as moisture retaining ability, keratin, skin irritation, skin elasticity, wrinkles, and the like, And completed the present invention.
본 발명의 하나의 목적은 수선화구근추출물, 백합구근추출물, 은방울꽃구근추출물 또는 상기 각 추출물의 분획물을 유효성분으로 포함하는 피부 보습용 화장료 조성물을 제공하는 것이다.One object of the present invention is to provide a cosmetic composition for skin moisturizing which comprises, as an active ingredient, a daffodil bulb extract, a lily bulb extract, a lily of the valley bulb extract or a fraction of each of the above extracts.
본 발명의 다른 목적은 수선화구근추출물, 백합구근추출물, 은방울꽃구근추출물 또는 상기 각 추출물의 분획물을 유효성분으로 포함하는 피부 탄력성 증가 또는 주름개선용 화장료 조성물을 제공하는 것이다.Another object of the present invention is to provide a cosmetic composition for increasing skin elasticity or improving wrinkles, which comprises as an active ingredient, a daffodil bulb extract, a lily bulb extract, a lily of the valley bulb extract or a fraction thereof.
본 발명의 또 다른 목적은 수선화구근추출물, 백합구근추출물, 은방울꽃구근추출물 또는 상기 각 추출물의 분획물을 유효성분으로 포함하는 피부건조증 예방 또는 치료용 약학 조성물에 관한 것이다.
Another object of the present invention is to provide a pharmaceutical composition for preventing or treating skin dryness, which comprises as an active ingredient, a solution of a bulb of Daffodil bulb, a bulb of lily bulb, a bulblet bulbous extract or a fraction of each of the above extracts.
본 발명자들은 부작용이 없이 피부 보습능을 향상시킬 수 있는 기능성 화장품을 개발하기 위하여, 다양한 연구를 수행하던 중, 식물의 구근에 주목하게 되었다. 피부 보습능의 향상과 관련하여 지금까지 사용되지 않은 식물의 구근을 사용할 경우, 새로운 효과를 나타내는 기능성 화장품을 제조할 수 있을 것으로 가정하고 다양한 구근을 시험한 결과, 수선화구근추출물, 백합구근추출물 또는 은방울꽃구근추출물이 피부 보습능을 향상시킬 수 있음을 확인하였다. 뿐만 아니라, 상기 각 추출물은 피부 보습능 이외에도 각질 개선효과, 피부자극 감소효과, 피부 탄력성 증가효과, 주름 개선효과 등의 다양한 측면에서 피부를 개선시키는 효과를 나타낼 수 있음을 확인하였으며, 이들 각 추출물을 개별적으로 사용할 경우보다는 이들을 조합하여 사용할 경우에 상술한 효과를 배가시킬 수 있음을 알 수 있었다.The present inventors paid attention to the bulbs of plants while carrying out various studies to develop functional cosmetics capable of improving skin moisturizing ability without side effects. Regarding the enhancement of skin moisturizing ability, when a bulb of a plant which has not been used up to now is used, it is assumed that a functional cosmetic exhibiting a new effect can be produced. Various bulbs were tested to find that the bulbous extract, lily bulb extract or lily of the valley It was confirmed that bulb extract could improve skin moisturizing ability. In addition to the skin moisturizing ability, each of the above-mentioned extracts showed the effect of improving the skin in various aspects such as the horny improving effect, the skin irritation reducing effect, the skin elasticity increasing effect and the wrinkle improving effect. It has been found that the above effects can be doubled in the case of using them in combination rather than individually.
따라서, 수선화구근추출물, 백합구근추출물, 은방울꽃구근추출물 또는 상기 각 추출물의 분획물은 각각 개별적으로 또는 조합하여 사용함으로써, 피부개선 효과를 나타내는 기능성 화장품의 유효성분으로 사용될 수 있음을 알 수 있었다.
Therefore, it was found that the use of the daffodil bulb extract, the lily bulb extract, the lily of the valley bulb extract, or the fractions of the above extracts individually or in combination enables to be used as an effective ingredient of a functional cosmetic exhibiting skin improving effect.
상술한 목적을 달성하기 위하여, 본 발명은 하나의 양태로서 수선화구근추출물 또는 이의 분획물, 백합구근추출물 또는 이의 분획물, 은방울꽃구근추출물 또는 이의 분획물 및 이들의 조합으로 구성된 군으로부터 선택되는 어느 하나를 포함하는, 피부 보습용 화장료 조성물을 제공한다.
In order to achieve the above-mentioned object, the present invention relates to a method for the production of a medicament for the prevention and / or treatment of cancer, comprising, as one embodiment, any one selected from the group consisting of a daffodil bulb extract or a fraction thereof, a lily bulb extract or a fraction thereof, a lavender bulb extract or a fraction thereof, And a cosmetic composition for moisturizing the skin.
본 발명의 용어 "수선화(Narcissus tazetta)"란, 1월에서 4월까지 피고 옆을 향해 피며, 풀잎은 가늘고 난초 잎같이 날렵하며 양파모양의 뿌리줄기를 가지고 있는 식물의 꽃을 의미한다. 상기 수선화의 구근을 마쇄하여 수득한 생즙은 부스럼을 치료하고, 꽃은 향유를 만들어 풍을 제거하며 발열, 백일해, 천식, 구토 등에 사용될 수 있다고 알려져 있다.The term " Narcissus tazetta "of the present invention refers to a plant flower blooming from January to April to the side of the defendant, the grass blade being thin and slender like an orchid leaf, and having an onion-like rootstock. The juice obtained by grinding the bulbs of the daffodil can be used to treat the blotches, and the flowers can be used to remove the wind by making perfume, and can be used for fever, pertussis, asthma, vomiting and the like.
본 발명의 용어 "백합(Lilium Candidum)"이란, 한방에서는 꽃이 피는 시기가 끝나고 영양분이 구근에 모이는 겨울철에 채취하여 생약으로 이용하여온 약용식물을 의미한다. 특히, 상기 백합의 구근은 민간요법으로서 대상포진, 피부 찰과상 등을 치료하는데 사용되어 왔다.The term "Lilium Candidum" of the present invention means a medicinal plant which has been harvested as a herbal medicine in the winter season when nutrients are collected at the end of a flowering period and nutrients are collected in a bulb. In particular, bulbs of the lily have been used as folk remedies for treating herpes zoster, skin abrasions, and the like.
본 발명의 용어 "은방울꽃(Leucojum aestivum)"이란, 유럽 원산이고, 높이 50∼100cm이며, 꽃은 종 모양으로 흰색이고, 4월 중순에 피는 꽃을 의미한다. 상기 은방울꽃은 헝가리와 우크라이나, 남부유럽, 터키, 발칸지역 등에서 민간요법에 사용되어 왔다. The term " Leucojum aestivum "of the present invention is European origin and 50 to 100 cm in height, and the flower is a bell-shaped white, which means a flower blooming in mid-April. The lily of the valley has been used in folk remedies in Hungary, Ukraine, southern Europe, Turkey, and the Balkans.
본 발명의 용어 "추출물"이란, 수선화구근, 백합구근 또는 은방울꽃구근을 추출하여 수득한 추출물을 의미하는데, 본 발명의 목적상, 상기 추출물은 수선화구근, 백합구근, 은방울꽃구근 또는 이들 각각의 분쇄물을 추출용매를 사용하여 추출한 결과물이 될 수 있으나, 이에 제한되지는 않고, 상기 결과물은 추출액, 추출액의 희석액 또는 농축액, 추출액을 건조하여 얻어지는 건조물, 또는 이들 조정제물 또는 정제물 등을 모두 포함할 수 있다. 이때 사용된 추출용매는 특별히 이에 제한되지 않으나, 일 례로서, 물, 탄소수 1 내지 6의 알콜(메탄올, 에탄올, 부탄올 등), 에틸아세테이트 또는 이들의 혼합 용매가 될 수 있고, 다른 예로서, 에틸아세테이트, 에탄올 등의 용매가 될 수 있으며, 또 다른 예로서, 에탄올을 용매로 사용할 수 있다.The term "extract " of the present invention means an extract obtained by extracting a daffodil bulb, a lily bulb or a lily of the valley, and for the purpose of the present invention, the extract is selected from the group consisting of a daffodil bulb, a lily bulb, But the present invention is not limited thereto. The resultant product may include a diluted solution or a concentrated solution of the extract, a dried product obtained by drying the extract, or any of these adjusted products or purified products. have. The extraction solvent may be, for example, water, an alcohol having 1 to 6 carbon atoms (methanol, ethanol, butanol, etc.), ethyl acetate or a mixed solvent thereof, Acetate, ethanol and the like, and as another example, ethanol can be used as a solvent.
본 발명의 용어 "분획물"이란 다양한 구성성분을 포함하는 혼합물로부터 특정성분 또는 특정 그룹을 분리하는 분획방법에 의하여 얻어진 결과물을 의미한다. 본 발명에서는 상기 수선화구근추출물, 백합구근추출물 또는 은방울꽃구근추출물을 대상으로 용매 분획법, 한외여과 분획법, 크로마토그래피 분획법 등의 다양한 방법을 적용하여 분획한 결과물이 될 수 있다.The term "fraction " of the present invention means a product obtained by a fractionation method for separating a specific component or a specific group from a mixture containing various constituents. In the present invention, fractions obtained by applying various methods such as a solvent fractionation method, an ultrafiltration fractionation method, a chromatography fractionation method and the like can be used for the extraction of the above-mentioned bulbous, lily bulb or lily of the bulbs.
특히, 용매 분획법을 적용할 경우, 이때 사용되는 용매의 종류는 피부 보습효과를 나타내는 한 특별히 제한되지 않으나, 일 례로서, 물, 알코올, 에틸렌글리콜, 부틸렌글리콜 등의 극성 용매; 또는 헥산(Hexane), 에틸 아세테이트(Ethyl acetate), 클로로포름(Chloroform), 디클로로메탄(Dichloromethane) 등의 비극성 용매 등을 단독으로 사용되거나 또는 2 종 이상 혼합하여 사용될 수 있고, 다른 예로서, 물, 탄소수 1 내지 4의 저급 알코올, 에틸렌글리콜 및 부틸렌글리콜로 이루어진 군으로부터 선택된 하나 이상일 수 있다.
In particular, when the solvent fractionation method is applied, the type of the solvent used at this time is not particularly limited as long as it exhibits skin moisturizing effect, and examples thereof include polar solvents such as water, alcohol, ethylene glycol and butylene glycol; Or nonpolar solvents such as hexane, ethyl acetate, chloroform and dichloromethane. These solvents may be used alone or in combination of two or more. Examples of the solvent include water, 1 to 4 lower alcohols, ethylene glycol, and butylene glycol.
본 발명의 용어 "피부 보습"이란, 피부의 수분손실(수분 증발) 등을 적절히 조절하여 피부조직의 항상성을 유지하는 모든 행위를 의미한다. The term " skin moisturizing "in the present invention means all actions that maintain the homeostasis of the skin tissue by appropriately controlling moisture loss (moisture evaporation) of the skin and the like.
본 발명에 있어서, 상기 피부 보습은 본 발명에서 제공하는 상기 수선화구근추출물, 백합구근추출물, 은방울꽃구근추출물 또는 상기 각 추출물의 분획물을 각각 개별적으로 또는 조합하여 피부에 처리함으로써 향상될 수 있으며, 이에 더하여, 각질 개선효과, 피부자극 감소효과 등의 다양한 측면에서 피부를 개선시키는 효과를 추가로 나타낼 수 있다. 상술한 수선화구근추출물, 백합구근추출물, 은방울꽃구근추출물 또는 상기 각 추출물의 분획물의 효과는 본 발명자에 의하여 최초로 규명되었다.
In the present invention, the skin moisturization can be improved by treating the skin with the skin of the present invention, the lily bulb extract, the lily of the valley bulb extract or the fractions of the respective extracts individually or in combination, , The effect of improving the exfoliation, the effect of reducing the irritation of the skin, and the like. The inventors of the present invention first clarified the effects of the above-mentioned bulb extracts, lily bulb extracts, lily of the valley bulbs or fractions thereof.
한편, 상기 화장료 조성물은 수선화구근추출물, 백합구근추출물 또는 은방울꽃구근추출물을 각각 개별적으로 포함하거나 조합하여 포함할 수 있는데, 상기 각 추출물을 조합하여 포함할 경우, 조합비는 특별히 이에 제한되지 않으나, 수선화구근추출물과 백합구근추출물을 포함할 경우, 일 례로서 9:1 내지 1:1(중량부), 다른 예로서 6:1 내지 1:1(중량부), 또 다른 예로서 4:3(중량부)가 될 수 있고; 수선화구근추출물과 은방울꽃구근추출물을 포함할 경우, 일 례로서 9:1 내지 1:1(중량부), 다른 예로서 6:1 내지 1:1(중량부), 또 다른 예로서 4:3(중량부)가 될 수 있으며; 백합구근추출물 또는 은방울꽃구근추출물을 포함할 경우, 일 례로서 9:1 내지 1:9(중량부), 다른 예로서 6:4 내지 4:6(중량부), 또 다른 예로서 5:5(중량부)가 될 수 있고; 수선화구근추출물, 백합구근추출물 및 은방울꽃구근추출물을 모두 포함할 경우, 일 례로서 9:1:1 내지 1:1:1(중량부), 다른 예로서 2:1:1 내지 1:1:1(중량부), 또 다른 예로서 4:3:3(중량부)가 될 수 있다.In addition, the cosmetic composition may include, but is not limited to, a combination of the above-mentioned extracts in combination, each of which may be individually or in combination with an extract of a lily of the valley, a lily of the valley or a lily of the valley. (Parts by weight) as an example, from 6: 1 to 1: 1 (parts by weight) as another example, and 4: 3 (parts by weight) as another example when the extract and the lily bulb extract are included, ); (Parts by weight), in another example from 6: 1 to 1: 1 (parts by weight), and as another example, from 4: 3 (parts by weight) Parts by weight); (Parts by weight) as an example, from 6: 4 to 4: 6 (parts by weight) as another example, and from 5: 5 (parts by weight) as another example when the lily bulb extract or lily of the valley Parts by weight); 1: 1 to 1: 1: 1 (parts by weight) as an example, and 2: 1: 1 to 1: 1: 1 (parts by weight) as another example in the case of containing all of the daffodil bulb extract, lily bulb extract and lily of the valley (Parts by weight), and as another example 4: 3: 3 (parts by weight).
또한, 상기 화장료 조성물에 포함되는 상기 각 추출물 또는 그의 분획물의 함량은 특별히 제한되지 않으나, 일 례로서, 상기 화장료 조성물의 총 중량에 대해서 0.001 중량% 내지 30 중량%의 양으로 포함될 수 있고, 다른 예로서 0.01 중량% 내지 10 중량%의 양으로 포함될 수 있다.
The content of each of the extracts or fractions thereof in the cosmetic composition is not particularly limited, but may be, for example, in an amount of 0.001 to 30% by weight based on the total weight of the cosmetic composition, In an amount of 0.01% by weight to 10% by weight.
본 발명의 일 실시예에 의하면, 수선화구근추출물, 백합구근추출물 또는 은방울꽃구근추출물을 각각 개별적으로 또는 조합하여 포함하는 크림 조성물을 제조하고(실시예 1), 이들 각 크림 조성물의 피부개선 효과를 검증한 결과, 수분 보유능 향상효과(표 2), 각질 개선효과(표 3 및 4) 및 피부자극 감소효과(표 5)를 나타내며, 특히 이들 각 추출물을 조합하여 모두 포함하는 크림 조성물이 가장 우수한 효과를 나타냄을 확인하였다.
According to one embodiment of the present invention, a cream composition comprising the daffodil bulb extract, the lily bulb extract or the lily of the valley bulb extract, individually or in combination, is prepared (Example 1) As a result, the cream composition containing both of these extracts exhibits the best effects (Table 2), the improvement of the keratin (Table 3 and 4) and the reduction of the skin irritation (Table 5) Respectively.
다른 하나의 양태로서 수선화구근추출물 또는 이의 분획물, 백합구근추출물 또는 이의 분획물, 은방울꽃구근추출물 또는 이의 분획물 및 이들의 조합으로 구성된 군으로부터 선택되는 어느 하나를 포함하는, 피부 탄력성 증가 또는 주름개선용 화장료 조성물을 제공한다.
In another embodiment, the cosmetic composition for enhancing skin elasticity or wrinkles comprises any one selected from the group consisting of a daffodil bulb extract or a fraction thereof, a lily bulb extract or a fraction thereof, a lavender bulb extract or a fraction thereof and a combination thereof. .
본 발명에서 제공하는 수선화구근추출물, 백합구근추출물, 은방울꽃구근추출물 또는 상기 각 추출물의 분획물은 피부 탄력성을 증가시키고, 주름을 개선시킬 수 있으므로, 피부 탄력성 증가 또는 주름개선용 화장료 조성물의 유효성분으로 사용될 수 있다. 이때, 사용된 수선화구근, 백합구근, 은방울꽃구근, 이들의 추출물, 상기 추출물의 분획물 및 상기 성분의 조합비는 상술한 바와 동일하다.
The present invention provides a cosmetic composition for increasing skin elasticity or improving wrinkles, which can improve skin elasticity and wrinkle, and can be used as an effective ingredient of a cosmetic composition for improving skin elasticity or wrinkle, . At this time, the combination ratio of the used daffodil bulbs, lily bulbs, lily of the valley, extracts thereof, fractions of the extracts and the components are the same as described above.
본 발명의 일 실시예에 의하면, 수선화구근추출물, 백합구근추출물 또는 은방울꽃구근추출물을 각각 개별적으로 또는 조합하여 포함하는 크림 조성물을 제조하고(실시예 1), 이들 각 크림 조성물의 피부개선 효과를 검증한 결과, 피부 탄력성 증가효과 및 주름 개선효과(표 6)를 나타내며, 특히 이들 각 추출물을 조합하여 모두 포함하는 크림 조성물이 가장 우수한 효과를 나타냄을 확인하였다.
According to one embodiment of the present invention, a cream composition comprising the daffodil bulb extract, the lily bulb extract or the lily of the valley bulb extract, individually or in combination, is prepared (Example 1) As a result, the skin elasticity-increasing effect and the wrinkle-reducing effect (Table 6) were shown. In particular, it was confirmed that the cream composition including all of these extracts showed the most excellent effect.
아울러, 본 발명에서 제공하는 상기 각 화장료 조성물은 피부 보습, 각질 개선, 피부자극 감소, 피부 탄력성 증가 또는 주름개선 효과를 나타내는 기능성 화장품을 제조하는데 사용될 수 있다.
In addition, each of the cosmetic compositions provided in the present invention can be used for producing a functional cosmetic exhibiting skin moisturizing, keratin-improving, skin irritation reduction, skin elasticity improvement or wrinkle-reducing effect.
본 발명의 용어 "기능성 화장품(cosmedical, cosmeceutical)"이란 화장품에 의약품의 전문적인 치료기능이 도입되어, 일반 화장품과 달리 생리활성적인 효능, 효과가 강조된 전문적인 기능성을 갖는 제품으로서, 피부의 미백에 도움을 주는 제품, 피부 주름개선에 도움을 주는 제품, 피부를 곱게 태우거나 자외선으로부터 피부를 보호하는데 도움을 주는 제품 중에서 보건복지부령이 정하는 화장품을 의미한다. The term "cosmedical, cosmeceutical" of the present invention refers to a product having a professional function that has a physiologically active effect and an effect emphasized, unlike general cosmetics, A product that helps, a product that helps to improve wrinkles, a product that helps protect skin from burns or UV rays.
본 발명의 기능성 화장품은 상기 수선화구근추출물, 백합구근추출물, 은방울꽃구근추출물, 상기 각 추출물의 분획물 등을 유효성분으로 포함하고, 통상적으로 사용되는 화장료를 추가로 함유할 수 있는데, 예를 들면 수용성 스킨제제화를 위하여 글리세롤, 프로필렌글리콜, 1,3-부틸렌글리콜, 솔비톨, 폴리에틸렌글리콜, 카르복시비닐 폴리머, 잔탄검, 카르복시메틸셀룰로오스, 하이드록시에틸셀룰로오스, 하이드록시메틸셀룰로오스, 로커스트빈검, 알란토인, 카라기난 등을 첨가할 수 있으며; 점도와 경도조절제로 밀납, 파라핀 왁스, 스테아릴알콜, 카르나우바 왁스, 칸데릴라 왁스 및 칼슘스테아레이트, 알루미늄스테아레이트, 아연스테아레이트, 위치하젤(witchhazel) 등을 사용할 수 있고; 자외선 흡수제로 부틸메톡시디벤조일메탄, 옥틸메톡시신나메이트 등을 사용할 수 있으며; 안료로는 이산화티탄, 미립자 이산화디탄, 카올린, 나이론 파우다, 탈크, 세리사이트, 마이카, 폴리메틸메타크릴레이트 등의 체질 안료와 황색산화철, 흑색산화철, 적색산화철, 울트라마린, 산화크롬, 수산화크롬 등의 착색안료를 사용할 수 있고; 보습제로 1,3-부틸렌글리콜, 농글리세린, 에틸렌글리콜 등과 키틴, 키토산, 히아론산, 하이알루로닌산, 젖산, 글리콜산 등의 천연보습 물질들을 이용할 수 있으며; 방부제로 파라옥시안식향산 에스테르류, 이미다졸리디닐우레아 등을 사용할 수 있을 뿐만 아니라, 상기한 성분들을 제품특성에 따라 1종 또는 2종이상 혼용 배합할 수도 있다.
The functional cosmetics of the present invention may further contain cosmetics commonly used as an active ingredient, such as the above-mentioned daffodil bulb extract, lily bulb extract, lily of the valley bulb extract, fractions of the respective extracts and the like, For formulation, glycerol, propylene glycol, 1,3-butylene glycol, sorbitol, polyethylene glycol, carboxyvinyl polymer, xanthan gum, carboxymethylcellulose, hydroxyethylcellulose, hydroxymethylcellulose, locust bean gum, allantoin, Can be added; Paraffin wax, stearyl alcohol, carnauba wax, candelilla wax and calcium stearate, aluminum stearate, zinc stearate, and witchhazel can be used as the viscosity and hardness adjusting agent; As the ultraviolet absorber, butylmethoxydibenzoylmethane, octylmethoxycinnamate and the like can be used; Examples of the pigment include extender pigments such as titanium dioxide, fine particulate dioxides, kaolin, nylon powder, talc, sericite, mica and polymethyl methacrylate, and pigments such as yellow iron oxide, black iron oxide, red iron oxide, ultramarine, chromium oxide, Of a coloring pigment; Natural moisturizing agents such as 1,3-butylene glycol, concentrated glycerin, ethylene glycol, and chitin, chitosan, hypalonic acid, hyaluronic acid, lactic acid and glycolic acid can be used as the moisturizing agent; As the preservative, p-hydroxybenzoic acid esters, imidazolidinyl urea, and the like can be used. In addition, one or more of the above-mentioned components may be blended according to the characteristics of the product.
본 발명의 기능성 화장품은 당업계에서 통상적으로 제조되는 어떠한 제형으로도 제조될 수 있으며, 예를 들어, 용액, 현탁액, 유탁액, 페이스트, 겔, 크림, 로션, 파우더, 비누, 계면활성제-함유 클린싱, 오일, 분말 파운데이션, 유탁액 파운데이션, 왁스 파운데이션 및 스프레이 등으로 제형화될 수 있으나, 이에 한정되는 것은 아니다. 보다 상세하게는, 유연 화장수, 영양 화장수, 영양 크림, 마사지 크림, 에센스, 아이 크림, 클렌징 크림, 클렌징 포옴, 클렌징 워터, 팩, 스프레이 또는 파우더의 제형으로 제조될 수 있다.The functional cosmetic composition of the present invention may be prepared in any form conventionally produced in the art and may be in the form of a solution, a suspension, an emulsion, a paste, a gel, a cream, a lotion, a powder, a soap, , Oil, powder foundation, emulsion foundation, wax foundation and spray, but is not limited thereto. More specifically, it can be manufactured in the form of a soft lotion, a nutritional lotion, a nutritional cream, a massage cream, an essence, an eye cream, a cleansing cream, a cleansing foam, a cleansing water, a pack, a spray or a powder.
본 발명의 제형이 페이스트, 크림 또는 겔인 경우에는 담체 성분으로서 동물성유, 식물성유, 왁스, 파라핀, 전분, 트라칸트, 셀룰로오스 유도체, 폴리에틸렌 글리콜, 실리콘, 벤토나이트, 실리카, 탈크 또는 산화아연 등이 이용될 수 있다.When the formulation of the present invention is a paste, cream or gel, an animal oil, vegetable oil, wax, paraffin, starch, tracant, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc or zinc oxide may be used as the carrier component .
본 발명의 제형이 파우더 또는 스프레이인 경우에는 담체 성분으로서 락토스, 탈크, 실리카, 알루미늄 히드록시드, 칼슘 실리케이트 또는 폴리아미드 파우더가 이용될 수 있고, 특히 스프레이인 경우에는 추가적으로 클로로플루오로히드로카본, 프로판/부탄 또는 디메틸 에테르와 같은 추진체를 포함할 수 있다.When the formulation of the present invention is a powder or a spray, lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder may be used as a carrier component. In the case of a spray, in particular, / Propane or dimethyl ether.
본 발명의 제형이 용액 또는 유탁액인 경우에는 담체 성분으로서 용매, 용해화제 또는 유탁화제가 이용되고, 예컨대 물, 에탄올, 이소프로판올, 에틸 카보네이트, 에틸 아세테이트, 벤질 알코올, 벤질 벤조에이트, 프로필렌글리콜, 1,3-부틸글리콜 오일, 글리세롤 지방족 에스테르, 폴리에틸렌 글리콜 또는 소르비탄의 지방산 에스테르가 있다.When the formulation of the present invention is a solution or an emulsion, a solvent, a dissolving agent or an emulsifying agent is used as a carrier component, and examples thereof include water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, , 3-butyl glycol oil, glycerol aliphatic ester, polyethylene glycol or sorbitan fatty acid esters.
본 발명의 제형이 현탁액인 경우에는 담체 성분으로서 물, 에탄올 또는 프로필렌 글리콜과 같은 액상의 희석제, 에톡실화 이소스테아릴 알코올, 폴리옥시에틸렌 소르비톨 에스테르 및 폴리옥시에틸렌 소르비탄 에스테르와 같은 현탁제, 미소결정성 셀룰로오스, 알루미늄 메타히드록시드, 벤토나이트, 아가 또는 트라칸트 등이 이용될 수 있다.In the case where the formulation of the present invention is a suspension, a carrier such as water, a liquid diluent such as ethanol or propylene glycol, a suspending agent such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, Cellulose, aluminum metahydroxide, bentonite, agar or tracant, etc. may be used.
본 발명의 제형이 계면-활성제 함유 클린징인 경우에는 담체 성분으로서 지방족 알코올 설페이트, 지방족 알코올 에테르 설페이트, 설포숙신산 모노에스테르, 이세티오네이트, 이미다졸리늄 유도체, 메틸타우레이트, 사르코시네이트, 지방산 아미드 에테르 설페이트, 알킬아미도베타인, 지방족 알코올, 지방산 글리세리드, 지방산 디에탄올아미드, 식물성 유, 라놀린 유도체 또는 에톡실화 글리세롤 지방산 에스테르 등이 이용될 수 있다.
When the formulation of the present invention is an interfacial active agent-containing cleansing, the carrier component may include aliphatic alcohol sulfate, aliphatic alcohol ether sulfate, sulfosuccinic acid monoester, isethionate, imidazolinium derivative, methyltaurate, sarcosinate, fatty acid amide Ether sulfates, alkylamidobetaines, aliphatic alcohols, fatty acid glycerides, fatty acid diethanolamides, vegetable oils, lanolin derivatives or ethoxylated glycerol fatty acid esters.
또 다른 양태로서, 수선화구근추출물 또는 이의 분획물, 백합구근추출물 또는 이의 분획물, 은방울꽃구근추출물 또는 이의 분획물 및 이들의 조합으로 구성된 군으로부터 선택되는 어느 하나를 포함하는, 피부 건조증 예방 또는 치료용 약학 조성물을 제공한다.
In another embodiment, there is provided a pharmaceutical composition for preventing or treating skin dryness comprising any one selected from the group consisting of a daffodil bulb extract or a fraction thereof, a lily bulb extract or a fraction thereof, a lily of the valley bulb extract or a fraction thereof, to provide.
본 발명에서 제공하는 수선화구근추출물, 백합구근추출물, 은방울꽃구근추출물 또는 상기 각 추출물의 분획물은 피부건조증과 같은 피부질환에 의하여 생성되는 각질의 형성을 억제하거나 또는 이미 형성된 각질을 감소시킬 수 있으므로, 각질을 형성하는 피부질환인 피부건조증의 예방 또는 치료용 약학 조성물의 유효성분으로 사용될 수 있다. 이때, 사용된 수선화구근, 백합구근, 은방울꽃구근, 이들의 추출물, 상기 추출물의 분획물 및 상기 성분의 조합비는 상술한 바와 동일하다.
The extracts of the daffodil bulbous extract, lily bulb extract, lily of the valley or extracts of the above extracts of the present invention can inhibit the formation of keratin formed by skin diseases such as dry skin, Which can be used as an active ingredient of a pharmaceutical composition for preventing or treating skin dryness, At this time, the combination ratio of the used daffodil bulbs, lily bulbs, lily of the valley, extracts thereof, fractions of the extracts and the components are the same as described above.
본 발명에서 제공하는 피부건조증의 예방 또는 치료용 약학 조성물은, 약학적 조성물의 제조에 통상적으로 사용하는 적절한 담체(자연적 또는 비자연적 담체), 부형제 또는 희석제를 추가로 포함하는 약학 조성물의 형태로 제조될 수 있다. 구체적으로, 상기 약학 조성물은, 각각 통상의 방법에 따라 피부건조증이 유발된 부위에 도포할 수 있는 파우더, 젤, 연고, 크림, 액체 또는 에어로졸과 같은 다양한 피부외용제의 형태로 제형화하여 사용될 수 있다. 본 발명에서, 상기 약학 조성물에 포함될 수 있는 담체, 부형제 및 희석제로는 락토즈, 덱스트로즈, 수크로스, 솔비톨, 만니톨, 자일리톨, 에리스리톨, 말티톨, 전분, 아카시아 고무, 알지네이트, 젤라틴, 칼슘 포스페이트, 칼슘 실리케이트, 셀룰로즈, 메틸 셀룰로즈, 미정질 셀룰로스, 폴리비닐 피롤리돈, 물, 메틸히드록시벤조에이트, 프로필히드록시벤조에이트, 탈크, 마그네슘 스테아레이트, 광물유, 콜라겐 등을 들 수 있다. 제제화 할 경우에는 보통 사용하는 충진제, 증량제, 결합제, 습윤제, 붕해제, 계면활성제 등의 희석제 또는 부형제를 사용하여 조제될 수 있다. 특히, 멸균된 수용액, 비수성용제, 현탁제, 유제, 동결건조 제제, 좌제 등이 포함될 수 있다. 비수성용제, 현탁제로는 프로필렌글리콜(propylene glycol), 폴리에틸렌 글리콜, 올리브 오일과 같은 식물성 기름, 에틸올레이트와 같은 주사 가능한 에스테르 등이 사용될 수 있다. 좌제의 기제로는 위텝솔(witepsol), 마크로골, 트윈(tween) 61, 카카오지, 라우린지, 글리세로제라틴 등이 사용될 수 있다.
The pharmaceutical composition for preventing or treating dry skin of the present invention provided in the present invention may be prepared in the form of a pharmaceutical composition further comprising an appropriate carrier (natural or non-natural carrier), an excipient or a diluent conventionally used in the production of a pharmaceutical composition . Specifically, the pharmaceutical composition may be formulated into various external preparations for skin such as powders, gels, ointments, creams, liquids or aerosols, which can be applied to areas where dry skin symptoms have been induced according to conventional methods . In the present invention, the carrier, excipient and diluent which may be contained in the pharmaceutical composition include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, Calcium silicate, cellulose, methylcellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, mineral oil, collagen and the like. In the case of formulation, it can be prepared using diluents or excipients such as fillers, extenders, binders, humectants, disintegrants, surfactants and the like which are usually used. In particular, sterilized aqueous solutions, non-aqueous solvents, suspensions, emulsions, freeze-dried preparations, suppositories and the like may be included. Examples of the suspending agent include propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like. Examples of the suppository base include witepsol, macrogol, tween 61, cacao butter, laurin, glycerogelatin and the like.
본 발명의 약학 조성물에 포함된 상기 각 추출물 또는 분획물의 함량은 특별히 이에 제한되지 않으나, 최종 조성물 총 중량을 기준으로 일 례로서 0.001 중량% 내지 30 중량%, 다른 예로서 0.01 중량% 내지 10 중량%의 양으로 포함될 수 있다.
The content of each of the extracts or fractions contained in the pharmaceutical composition of the present invention is not particularly limited, but may be, for example, 0.001 to 30% by weight, in other words 0.01 to 10% by weight, based on the total weight of the final composition, As shown in FIG.
상기 본 발명의 약학 조성물은 약제학적으로 유효한 양으로 투여될 수 있는데, 본 발명의 용어 "약제학적으로 유효한 양"이란 의학적 치료 또는 예방에 적용 가능한 합리적인 수혜/위험 비율로 질환을 치료 또는 예방하기에 충분한 양을 의미하며, 유효 용량 수준은 질환의 중증도, 약물의 활성, 환자의 연령, 체중, 건강, 성별, 환자의 약물에 대한 민감도, 사용된 본 발명 조성물의 투여 시간, 투여 경로 및 배출 비율 치료기간, 사용된 본 발명의 조성물과 배합 또는 동시 사용되는 약물을 포함한 요소 및 기타 의학 분야에 잘 알려진 요소에 따라 결정될 수 있다. 본 발명의 약학 조성물은 단독으로로 투여하거나 공지된 치주질환 치료용 약학 조성물과 병용하여 투여될 수 있다. 상기 요소를 모두 고려하여 부작용 없이 최소한의 양으로 최대 효과를 얻을 수 있는 양을 투여하는 것이 중요하다.
The pharmaceutical composition of the present invention can be administered in a pharmaceutically effective amount. The term "pharmaceutically effective amount " of the present invention means a therapeutic or prophylactic treatment of a disease at a reasonable benefit / risk ratio applicable to medical treatment or prevention And the effective dose level refers to the level of the disease to be treated, the severity of the disease, the activity of the drug, the age, body weight, health, sex, sensitivity of the patient to the drug, Duration, duration of administration, factors involved in combination with or contemporaneously with the composition of the present invention, and other factors well known in the medical arts. The pharmaceutical composition of the present invention may be administered alone or in combination with a pharmaceutical composition for treating periodontal disease known in the art. It is important to take into account all of the above factors and administer an amount that will achieve the maximum effect in the least amount without side effects.
본 발명의 약학 조성물의 투여량은 사용목적, 질환의 중독도, 환자의 연령, 체중, 성별, 기왕력, 또는 유효성분으로서 사용되는 물질의 종류 등을 고려하여 당업자가 결정할 수 있다.
The dosage of the pharmaceutical composition of the present invention can be determined by those skilled in the art in consideration of the purpose of use, the degree of addiction to the disease, the age, body weight, sex, history, or kind of the substance used as the active ingredient.
본 발명의 수선화구근추출물, 백합구근추출물, 은방울꽃구근추출물 또는 상기 각 추출물의 분획물을 포함하는 조성물을 이용하면, 수분 보유능 향상효과, 각질 개선효과, 피부자극 감소효과, 피부 탄력성 증가효과, 주름 개선효과 등의 다양한 측면에서 피부를 개선시키는 효과를 나타낼 수 있으므로, 피부개선용 기능성 화장품의 개발에 널리 활용될 수 있을 것이다.
Using the composition comprising the daffodil bulb extract, the lily bulb extract, the lily of the valley bulb extract or the fraction of each of the above extracts of the present invention, the effect of improving water retention ability, the exfoliation improving effect, the skin irritation reducing effect, the skin elasticity increasing effect, And the like, it can be widely used in the development of functional cosmetics for skin improvement.
이하 본 발명을 실시예를 통하여 보다 상세하게 설명한다. 그러나 이들 실시예는 본 발명을 예시적으로 설명하기 위한 것으로 본 발명의 범위가 이들 실시예에 한정되는 것은 아니다.
Hereinafter, the present invention will be described in more detail with reference to examples. However, these examples are for illustrative purposes only, and the scope of the present invention is not limited to these examples.
실시예Example
1: 구근 추출물을 포함하는 크림 조성물의 제조 1: Preparation of cream composition containing bulb extract
실시예Example
1-1: 구근 추출물의 수득 1-1: Obtaining of bulb extract
건조된 수선화비늘줄기(Narcissus Tazetta Bulb), 백합구근(Lilium Candidum Bulb) 또는 은방울꽃구근(Leucojum Aestivum Bulb) 100g에 에탄올 1L를 가하고, 냉각 콘덴서가 구비된 추출기를 사용하여 10시간동안 가열하여 각각의 반응물을 수득하였다. 상기 수득한 각 반응물을 300메쉬 여과포로 여과하여 액상 성분을 수득하고, 상기 수득한 액상 성분을 진공증류하여 에탄올 성분을 제거하였으며, 잔류물을 0.45㎛ 필터로 여과한 다음, 여과된 반응물에 글리세린을 첨가하여 각각 300ml의 구근 추출물을 수득하였다.
1 L of ethanol was added to 100 g of dried Narcissus Tazetta Bulb, Lilium Candidum Bulb or Leucojum Aestivum Bulb and heated for 10 hours using an extractor equipped with a cooling condenser, ≪ / RTI > Each of the obtained reactants was filtered with a 300-mesh filter cloth to obtain a liquid component, and the obtained liquid component was vacuum distilled to remove the ethanol component. The residue was filtered through a 0.45 μm filter, and glycerin To give 300 ml bulb extracts, respectively.
실시예Example
1-2: 크림 조성물의 제조 1-2: Preparation of Cream Composition
유상 성분과 상기 실시예 1-1에서 제조된 각각의 구근 추출물을 포함하는 수성 성분을 혼합하고, 유화하여 크림 조성물을 제조하였다.An oily component was mixed with an aqueous component containing each of the bulb extracts prepared in Example 1-1 and emulsified to prepare a cream composition.
먼저, 70℃ 조건에서 유상성분을 균일하게 혼합하여 유상혼합물을 수득하였다.First, the oil phase components were uniformly mixed at 70 DEG C to obtain an oil phase mixture.
다음으로, 70℃ 조건에서 상기 실시예 1-1에서 제조된 각각의 구근 추출물을 포함하는 수성 성분을 혼합 및 용해시켜서, 수상혼합물을 수득하였다.Next, an aqueous mixture containing each of the bulb extracts prepared in Example 1-1 was mixed and dissolved at 70 캜 to obtain a water-based mixture.
끝으로, 70℃ 조건에서 상기 수득한 수상혼합물에 유상혼합물을 가하여 유화시키고, 유화된 혼합물을 탈기시킨 다음, 30℃로 냉각시켜서, 크림 조성물을 제조하였다. 이때, 상기 유상 성분과 수상 성분의 종류와 함량은 하기 표 1에 나타내었다.
Finally, the oil mixture was added to the aqueous mixture obtained at 70 ° C to emulsify the emulsion, the emulsified mixture was deaerated, and then cooled to 30 ° C to prepare a cream composition. At this time, the types and content of the oil component and water component are shown in Table 1 below.
버터
오일Emulsifiers and emulsifying agents
butter
oil
2
108.7
2
10
2
108.7
2
10
2
108.7
2
10
2
108.7
2
10
2
108.7
2
10
점증제
보습제
항염제
방부제
EDTA-3NA
중화제
향료
색소
수선화구근추출물
백합구근추출물
은방울꽃구근추출물Purified water
Incrementer
Moisturizer
Anti-inflammatory agent
antiseptic
EDTA-3NA
corrector
Spices
Pigment
Daffodil bulb extract
Lily bulb extract
Lily of the valley bulb extract
0.31
7
1.5
1.5
0.2
0.5
적량
적량
-
-
-To 100
0.31
7
1.5
1.5
0.2
0.5
Suitable amount
Suitable amount
-
-
-
0.31
7
1.5
1.5
0.2
0.5
적량
적량
0.4
-
-To 100
0.31
7
1.5
1.5
0.2
0.5
Suitable amount
Suitable amount
0.4
-
-
0.31
7
1.5
1.5
0.2
0.5
적량
적량
-
0.3
-To 100
0.31
7
1.5
1.5
0.2
0.5
Suitable amount
Suitable amount
-
0.3
-
0.31
7
1.5
1.5
0.2
0.5
적량
적량
-
-
0.3To 100
0.31
7
1.5
1.5
0.2
0.5
Suitable amount
Suitable amount
-
-
0.3
0.31
7
1.5
1.5
0.2
0.5
적량
적량
0.4
0.3
0.3To 100
0.31
7
1.5
1.5
0.2
0.5
Suitable amount
Suitable amount
0.4
0.3
0.3
실시예Example
2: 크림 조성물의 효능 평가 2: Evaluation of efficacy of cream composition
상기 실시예 1-2에서 제조한 크림 조성물이 피부개선에 미치는 효과를 평가하였다.
The effect of the cream composition prepared in Example 1-2 on skin improvement was evaluated.
실시예Example
2-1: 수분 2-1: Moisture
보유능Possession
평가 evaluation
25℃, 상대습도 45%의 항온 항습실에서 20명의 피시험자의 팔의 안쪽피부의 수분 보유능을 피부수분함량측정기(Skin surface hygrometer, 모델명: SKICON-200, 일본 IBS사 제품)를 사용하여 측정한 다음, 상기 피부에 상기 실시예 1-2에서 제조한 각각의 크림 조성물을 2mg/㎠의 수준으로 도포하고, 1시간 및 3시간이 경과된 후의 수분 보유능을 측정한 다음, 사전 측정된 수분 보유능을 기준값(100)으로 설정하여 상대적인 수분 보유능을 산출하고 비교하였다(표 2).
The water retention capacity of the inner skin of the arms of 20 subjects was measured using a skin surface hygrometer (model name: SKICON-200, manufactured by IBS Co., Ltd.) at 25 ° C and a relative humidity of 45% Each of the skin creams prepared in Example 1-2 was applied to the skin at a level of 2 mg / cm 2, the water retention capacity after 1 hour and 3 hours elapsed was measured, (100), and the relative water holding ability was calculated and compared (Table 2).
실험군 1
실험군 2
실험군 3
실험군 4Control group
Experiment 1
Experiment 2
Experiment group 3
Experiment group 4
100
100
100
100100
100
100
100
100
138
142
137
197107
138
142
137
197
115
117
121
180107
115
117
121
180
상기 표 2에서 보듯이, 모든 실험군의 크림 조성물은 대조군의 크림 조성물에 비하여 상대적으로 높은 수분 보유능을 나타내었고, 도포 후 1시간이 경과된 시점에서의 수분 보유능이 3시간이 경과된 시점에서의 수분 보유능보다 상대적으로 높은 값을 나타냄을 확인하였다.As shown in Table 2, the cream compositions of all the experimental groups showed a relatively high water retention ability as compared with the cream composition of the control group, and the moisture content at the point of time when the water retention ability at 1 hour after the application was 3 hours passed Which is relatively higher than the holding capacity.
또한, 실험군의 수분 보유능을 비교하면, 도포 후 1시간 및 3시간이 경과된 시점에서는 3가지 추출물을 모두 포함하는 크림 조성물(실험군 4)이 가장 높은 수준의 수분 보유능을 나타냄을 확인하였다.In addition, when the water retention capacity of the experimental group was compared, it was confirmed that the cream composition (Experiment group 4) containing all three extracts showed the highest water retention ability at 1 hour and 3 hours after application.
아울러, 1가지 추출물을 포함하는 실험군 1 내지 3을 비교하면, 1시간 경과후에는 백합구근 추출물을 포함하는 크림 조성물(실험군 2)이 가장 높은 수분 보유능을 나타낸 반면, 3시간 경과후에는 은방울꽃구근 추출물을 포함하는 크림 조성물(실험군 3)이 가장 높은 수분 보유능을 나타냄을 확인하였으므로, 짧은 시간동안 수분 보유능을 향상시키는 효과는 백합구근 추출물을 포함하는 크림 조성물이 우수하지만, 수분 보유능을 오랫동안 유지시키는 효과는 은방울꽃구근 추출물을 포함하는 크림 조성물이 우수함을 알 수 있었다.
In addition, when the experimental groups 1 to 3 containing one extract were compared with each other, the cream composition (experimental group 2) containing the lily bulb extract showed the highest water holding ability after 1 hour, while after 3 hours, the lily of the bulb extract (Experimental group 3) showed the highest water retention capacity. Therefore, the effect of improving the moisture retention ability for a short period of time is superior to the cream composition containing the lily bulb extract, but the effect of maintaining the water retention ability for a long time It was found that the cream composition containing the lily of the valley extract was superior.
실시예Example
2-2: 피부 각질 2-2: Horny skin
개선능Improvement ability
평가 evaluation
30세에서 50세까지의 여성 20명을 대상으로 팔 안쪽의 4cm X 4cm의 영역을 휴대용 현미경으로 촬영하여 각질이 형성된 부분의 비율을 측정하였다. 이어, 상기 측정된 영역에 상기 실시예 1-2에서 제조한 각각의 크림 조성물을 2주동안 도포한 다음, 동일한 영역에 포함된 각질 형성부의 비율을 측정하였다(표 3).
The area of 4 cm x 4 cm inside the arm was photographed with a hand-held microscope to measure the proportion of the horny part in 20 women aged 30 to 50 years. Next, each of the cream compositions prepared in Example 1-2 was applied to the measured region for 2 weeks, and the ratio of keratin-forming portions contained in the same region was measured (Table 3).
실험군 1
실험군 2
실험군 3
실험군 4Control group
Experiment 1
Experiment 2
Experiment group 3
Experiment group 4
15.2
15.2
15.1
15.115.2
15.2
15.2
15.1
15.1
5.2
5.4
5.7
3.28.8
5.2
5.4
5.7
3.2
상기 표 3에서 보듯이, 모든 실험군의 크림 조성물은 대조군의 크림 조성물에 비하여 상대적으로 높은 각질개선 효과를 나타내었고, 3가지 추출물을 모두 포함하는 크림 조성물(실험군 4)이 가장 높은 수준의 각질개선 효과를 나타냄을 확인하였다. As shown in Table 3, the cream compositions of all the experimental groups showed a relatively high keratinization effect as compared with the cream composition of the control group, and the cream composition (experimental group 4) containing all three extracts showed the highest level of keratin- Respectively.
아울러, 1가지 추출물을 포함하는 실험군 1 내지 3을 비교하면, 수선화구근추출물을 포함하는 크림 조성물(실험군 1)이 근소한 차이로 다른 구근추출물을 포함하는 크림 조성물(실험군 2 및 3) 보다도 상대적으로 우수한 각질 개선효과를 나타냄을 알 수 있었다.
Comparing experimental groups 1 to 3 containing one extract showed that the cream composition (Experiment group 1) containing the Daffodil bulb extract was relatively superior to the cream composition (Experiment groups 2 and 3) containing other bulb extracts with a slight difference It was found that the effect of improving the keratin was exhibited.
한편, 상기 20명의 피실험자를 대상으로 설문을 통해서 피부건조 개선효과를 3단계(개선없음, 약간의 개선 및 상당한 개선)로 나누어 평가하였다(표 4).
On the other hand, the skin dryness improvement effect of the 20 subjects was divided into three stages (no improvement, slight improvement and significant improvement) (Table 4).
실험군 1
실험군 2
실험군 3
실험군 4Control group
Experiment 1
Experiment 2
Experiment group 3
Experiment group 4
2
1
2
016
2
One
2
0
8
9
9
53
8
9
9
5
10
10
9
15One
10
10
9
15
상기 표 4에서 보듯이, 모든 실험군의 크림 조성물은 대조군의 크림 조성물에 비하여 상대적으로 높은 피부건조 개선효과를 나타내었고, 특히 3가지 추출물을 모두 포함하는 크림 조성물(실험군 4)이 가장 높은 수준의 피부건조 개선효과를 나타냄을 확인하였다.
As shown in Table 4, the cream composition of all the experimental groups showed a relatively higher skin dryness improvement than the cream composition of the control group. In particular, the cream composition (Experiment group 4) containing all three extracts showed the highest level of skin It was confirmed that the improvement effect of drying was shown.
실시예Example
2-3: 피부에 미치는 영향 평가 2-3: Evaluation of skin effect
상기 실시예 1-2에서 제조한 각각의 크림 조성물을 포함하는 로션을 제조하고, 상기 제조된 각 로션을 건성피부의 여성 75명(각 샘플당 15명씩)에 대해 세안 후 사용하도록 설정한 다음, 피부에 미치는 효과(피부자극, 피부 매끄러움 및 피부당김 개선)를 5점 척도법(1점:매우 약함, 2점:약함, 3점:보통, 4점:강함, 5점:매우 강함)으로 평가하고, 이들의 평균값을 비교하였다(표 5).
A lotion containing each of the cream compositions prepared in Example 1-2 was prepared, and each lotion thus prepared was set to be used after cleansing 75 female (15 per each sample) of dry skin, (Skin irritation, skin smoothness and skin pulling improvement) were evaluated by a 5-point scale method (1 point: very weak, 2 points: weak, 3 points: normal, 4 points: strong, 5 points: very strong) , And the mean values of these were compared (Table 5).
실험군 1
실험군 2
실험군 3
실험군 4Control group
Experiment 1
Experiment 2
Experiment group 3
Experiment group 4
1.7
1.8
1.7
1.41.9
1.7
1.8
1.7
1.4
3.5
3.4
3.2
3.93.0
3.5
3.4
3.2
3.9
3.6
3.5
3.4
4.13.1
3.6
3.5
3.4
4.1
상기 표 5에서 보듯이, 모든 실험군의 크림 조성물을 포함하는 로션은 대조군의 크림 조성물을 포함하는 로션에 비하여 피부에 미치는 영향이 상대적으로 높은 수준임을 확인하였다.As shown in Table 5, it was confirmed that the lotion containing the cream composition of all the experimental groups had a relatively high effect on the skin as compared with the lotion containing the cream composition of the control group.
구체적으로, 피부자극에 대하여는 대조군의 크림 조성물을 포함하는 로션이 가장 높은 수준으로 피부를 자극하는 반면, 3가지 추출물을 모두 포함하는 크림 조성물(실험군 4)을 포함하는 로션이 가장 낮은 수준으로 피부를 자극하였고, 그 다음으로, 수선화구근추출물 및 은방울꽃구근추출물을 포함하는 크림 조성물(실험군 1 및 3)을 포함하는 로션이 낮은 수준으로 피부를 자극하였으며, 백합구군추출물을 포함하는 크림조성물(실험군 2)을 포함하는 로션이 비교적 높은 수준으로 피부를 자극함을 확인하였다. Specifically, for skin irritation, the lotion containing the cream composition of the control group stimulates the skin to the highest level, while the lotion containing the cream composition containing all three extracts (experimental group 4) , Followed by a moisturizing lotion containing cream compositions (Experiments 1 and 3), which included a daffodil bulb extract and a lily of the valley extract. The cream composition (lane 2) Was found to stimulate the skin to a relatively high level.
다음으로, 피부 매끄러움에 대하여는 대조군의 크림 조성물을 포함하는 로션이 가장 낮은 수준의 매끄러움을 나타낸 반면, 3가지 추출물을 모두 포함하는 크림 조성물(실험군 4)을 포함하는 로션이 가장 높은 수준의 매끄러움을 나타내었고, 그 다음으로, 수선화구근추출물을 포함하는 크림 조성물(실험군 1)을 포함하는 로션, 백합구근추출물을 포함하는 크림 조성물(실험군 2)을 포함하는 로션 및 은방울꽃구근추출물을 포함하는 크림 조성물(실험군 3)을 포함하는 로션이 순차적인 수준으로 매끄러움을 나타냄을 확인하였다.Next, the lotion containing the cream composition of the control group showed the lowest level of smoothness for skin smoothness, while the lotion comprising the cream composition (Experiment group 4) containing all three extracts showed the highest level of smoothness , Followed by a lotion comprising a cream composition (Experimental Group 1) containing a daffodil bulb extract, a cream composition comprising a cream composition (Experimental Group 2) comprising a lily bulb extract, and a cream composition comprising a lavender bulb extract 3) showed smoothness to a sequential level.
끝으로, 피부당김 개선에 대하여는 대조군의 크림 조성물을 포함하는 로션이 가장 낮은 수준의 피부당김 개선효과를 나타낸 반면, 3가지 추출물을 모두 포함하는 크림 조성물(실험군 4)을 포함하는 로션이 가장 높은 수준의 피부당김 개선효과를 나타내었고, 그 다음으로, 수선화구근추출물을 포함하는 크림 조성물(실험군 1)을 포함하는 로션, 백합구근추출물을 포함하는 크림 조성물(실험군 2)을 포함하는 로션 및 은방울꽃구근추출물을 포함하는 크림 조성물(실험군 3)을 포함하는 로션이 순차적인 수준으로 피부당김 개선효과를 나타냄을 확인하였다.
Finally, the lotion containing the cream composition of the control group showed the lowest level of skin tightening improvement, while the lotion containing the cream composition (experimental group 4) containing all three extracts showed the highest level , Followed by a lotion containing a cream composition (experimental group 1) containing a daffodil bulb extract, a lotion containing a cream composition (experimental group 2) containing a lily bulb extract and a lily of the valley extract (Experimental Group 3) showed the effect of improving skin pulling to a sequential level.
실시예Example
2-4: 주름 개선에 미치는 영향 평가 2-4: Evaluation of effect on wrinkle improvement
30대 여성 80명을 10명씩 8개조로 나누어 4주 동안 매일 아침, 저녁으로 상기 실시예 1-2에서 제조한 각각의 크림 조성물을 피부에 도포하였다. 상기 각각의 크림 조성물의 도포 이전과 이후의 피부를 대상으로 Dermascan-C(Cortex tecnology, Denmark)를 사용하여 피부 진피 치밀도를 측정하고, 도포 이후 측정된 값과 도포 이전에 측정된 값의 차이를 산출하여 비교하였다. 상기 피부 진피 치밀도는 측정값이 증가할 수록 피부탄력이 우수한 것으로 평가될 수 있다.80 women in their thirties were divided into 8 groups of 10 persons each, and each cream composition prepared in Example 1-2 was applied to the skin for 4 weeks each morning and evening. The dermal density of the dermis was measured using Dermascan-C (Cortex technology, Denmark) before and after application of each of the above cream compositions, and the difference between the measured value after application and the measured value before application Respectively. The dermal density of the skin can be evaluated as being superior to skin elasticity as the measured value increases.
또한, 피부 주름 개선효과는 상기 각각의 크림 조성물의 도포 이전과 이후의 피부를 육안으로 관찰하여 5점 척도법에 의하여 평가하였다. 이때, 실험군 1의 크림 조성물을 처리하여 개선된 수준을 기준(100)으로 하여, 각 실험군 및 대조군의 크림 조성물을 처리하여 피부 주름이 개선된 수준을 환산하여 평가하였다(표 6).
In addition, the effect of improving the wrinkles of the skin was evaluated by 5-point scaling method by visually observing the skin before and after the application of each cream composition. At this time, the cream composition of Experimental Group 1 was treated, and the cream composition of each experimental group and the control group was treated with the improved level as the criterion (100), and the skin wrinkles were evaluated in terms of improved levels.
실험군 1
실험군 2
실험군 3
실험군 4Control group
Experiment 1
Experiment 2
Experiment group 3
Experiment group 4
3.08
3.25
3.11
4.562.73
3.08
3.25
3.11
4.56
100
116
109
13772
100
116
109
137
상기 표 6에서 보듯이, 모든 실험군의 크림 조성물은 대조군의 크림 조성물에 비하여 피부 진피 치밀도를 높은 수준으로 증가시키고, 향상된 주름 개선 효과를 나타냄을 확인하였다.
As shown in Table 6, it was confirmed that the cream composition of all the experimental groups increased the dermal density of the skin dermis to a higher level than the cream composition of the control group, and exhibited an improved wrinkle-reducing effect.
구체적으로, 피부 진피 치밀도에 대하여는, 대조군의 크림 조성물이 가장 낮은 수준으로 피부를 증가시키는 반면, 3가지 추출물을 모두 포함하는 크림 조성물(실험군 4)이 가장 높은 수준으로 증가시켰으며, 그 다음으로, 백합구군추출물을 포함하는 크림조성물(실험군 2), 은방울꽃구근추출물을 포함하는 크림 조성물(실험군 3) 및 수선화구근추출물을 포함하는 크림 조성물(실험군 1)이 순차적인 수준으로 피부 진피 치밀도를 증가시킴을 확인하였다.Specifically, for skin dermal density, the cream composition of the control group increased skin to the lowest level, while the cream composition (experimental group 4) containing all three extracts increased to the highest level, followed by , A cream composition (Experimental Group 2) containing a lily extract, a cream composition (Experiment group 3) containing a lily of the valley extract, and a cream composition (Experiment group 1) containing a narcissus bulb extract were successively increased in skin dermal density Respectively.
아울러, 주름 개선 효과에 대하여는, 대조군의 크림 조성물이 가장 낮은 수준의 주름 개선효과를 나타내는 반면, 3가지 추출물을 모두 포함하는 크림 조성물(실험군 4)이 가장 높은 수준의 주름 개선효과를 나타내었으며, 그 다음으로, 백합구군추출물을 포함하는 크림조성물(실험군 2), 은방울꽃구근추출물을 포함하는 크림 조성물(실험군 3) 및 수선화구근추출물을 포함하는 크림 조성물(실험군 1)이 순차적인 수준으로 주름 개선효과를 나타냄을 확인하였다.
As for the wrinkle-improving effect, the cream composition of the control group showed the lowest level of wrinkle-reducing effect, while the cream composition containing all three extracts (Experiment group 4) showed the highest level of wrinkle- Next, the cream composition (Experiment 2) containing the Lily Ward extract, the cream composition (Experiment group 3) containing the Lily of the Valley flowers extract and the cream composition (Experiment group 1) containing the Drosophila bulb extract were sequentially Respectively.
상기 실시예 2-1 내지 2-4의 결과를 종합하면, 수선화구근추출물, 백합구근추출물 또는 은방울꽃구근추출물은 수분 보유능 향상효과, 각질 개선효과, 피부자극 감소효과, 피부 탄력성 증가효과, 주름 개선효과 등의 다양한 측면에서 피부를 개선시키는 효과를 나타내었고, 상기 3가지 추출물을 모두 포함하는 조성물의 경우에는 상기 각 추출물을 개별적으로 사용할 경우보다도 현저하게 우수한 효과를 나타냄을 알 수 있었다.
The results of Examples 2-1 to 2-4 show that the effect of improving the water retention ability, the exfoliation improving effect, the skin irritation decreasing effect, the skin elasticity increasing effect, the wrinkle improving effect, the lily of the bulb extract or the lily of the valley bulb extract, . In addition, it was found that the composition containing all of the above three extracts exhibited remarkably excellent effects as compared with the case of using each of the above extracts individually.
본 명세서는 본 발명의 기술 분야에서 통상의 지식을 가진 자이면 충분히 인식하고 유추할 수 있는 내용은 그 상세한 기재를 생략하였으며, 본 명세서에 기재된 구체적인 예시들 이외에 본 발명의 기술적 사상이나 필수적 구성을 변경하지 않는 범위내에서 보다 다양한 변형이 가능하다. 따라서 본 발명은 본 명세서에서 구체적으로 설명하고 예시한 것과 다른 방식으로 실시될 수 있으며, 이는 본 발명의 기술 분야에 통상의 지식을 가진 자이면 이해할 수 있는 사항이다.It is to be understood that both the foregoing general description and the following detailed description of the present invention are exemplary and explanatory and are intended to provide further explanation of the invention as claimed. More variations are possible within a range that does not. Accordingly, the present invention may be embodied in other ways than those specifically described and illustrated herein, and will be understood by those skilled in the art.
Claims (8)
A cosmetic composition for skin moisturizing, which comprises any one selected from the group consisting of a sperm bulb extract or a fraction thereof, a lily bulb extract or a fraction thereof, a lily of the valley bulb extract or a fraction thereof, and a combination thereof.
상기 수선화구근추출물과 백합구근추출물을 포함하는 경우, 이들의 혼합비는 9:1 내지 1:1(중량부)인 것인 조성물.
The method according to claim 1,
Wherein the mixing ratio thereof is from 9: 1 to 1: 1 (parts by weight) when the above-described bulb extract and lily bulb extract are included.
상기 수선화구근추출물과 은방울꽃구근추출물을 포함하는 경우, 이들의 혼합비는 9:1 내지 1:1(중량부)인 것인 조성물.
The method according to claim 1,
Wherein the mixing ratio of the above-mentioned daffodil bulb extract and lily of the valley is 9: 1 to 1: 1 (parts by weight).
상기 백합구근추출물과 은방울꽃구근추출물을 포함하는 경우, 이들의 혼합비는 9:1 내지 1:9(중량부)인 것인 조성물.
The method according to claim 1,
Wherein the mixing ratio of the lily bulb extract and the lily of the valley is 9: 1 to 1: 9 (parts by weight).
상기 수선화구근추출물, 백합구근추출물 및 은방울꽃구근추출물을 포함하는 경우, 이들의 혼합비는 9:1:1 내지 1:1:1(중량부)인 것인 조성물.
The method according to claim 1,
Wherein the mixing ratio of the above-mentioned daffodil bulb extract, lily bulb extract and lily of the valley is 9: 1: 1 to 1: 1: 1 (parts by weight).
상기 조성물은 각질 개선효과 및 피부자극 감소효과를 추가로 나타내는 것인 조성물.
The method according to claim 1,
Wherein the composition further exhibits an exfoliation effect and a skin irritation reducing effect.
A cosmetic composition for enhancing skin elasticity or wrinkle comprising any one selected from the group consisting of a daffodil bulb extract or a fraction thereof, a lily bulb extract or a fraction thereof, a lily of the valley bulb extract or a fraction thereof and a combination thereof.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020150040919A KR102189330B1 (en) | 2015-03-24 | 2015-03-24 | A cosmetic composition for skin improvement comprising bulb extract |
| KR1020200167800A KR102309958B1 (en) | 2015-03-24 | 2020-12-03 | A cosmetic composition for skin improvement comprising bulb extract |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020150040919A KR102189330B1 (en) | 2015-03-24 | 2015-03-24 | A cosmetic composition for skin improvement comprising bulb extract |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020200167800A Division KR102309958B1 (en) | 2015-03-24 | 2020-12-03 | A cosmetic composition for skin improvement comprising bulb extract |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20160114794A true KR20160114794A (en) | 2016-10-06 |
| KR102189330B1 KR102189330B1 (en) | 2020-12-10 |
Family
ID=57164234
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020150040919A KR102189330B1 (en) | 2015-03-24 | 2015-03-24 | A cosmetic composition for skin improvement comprising bulb extract |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR102189330B1 (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107137315A (en) * | 2017-05-25 | 2017-09-08 | 甘肃青黛中草药美容研究有限责任公司 | It is a kind of that there are the skin care item for nourishing Shu Min effects by active component of fresh lily bulb extract |
| KR20180042541A (en) * | 2016-10-18 | 2018-04-26 | 주식회사 코리아나화장품 | Cosmetic composition comprising the very high-pressure extract of narcissus tazetta bulb fermentation |
| KR20200012487A (en) * | 2018-07-27 | 2020-02-05 | 제주대학교 산학협력단 | Cosmetic composition containing Narcissus extract |
| WO2021249960A1 (en) | 2020-06-09 | 2021-12-16 | Clariant International Ltd | Compositions comprising narcissus spp. plant extract and use thereof |
-
2015
- 2015-03-24 KR KR1020150040919A patent/KR102189330B1/en active IP Right Grant
Non-Patent Citations (3)
| Title |
|---|
| 네이버 블로그, [마몽드] 수선화 알뿌리 속 수분 이야기 : 수선화 수분저장 크림, [online], (2014.05.20. 공개)* * |
| 네이버 블로그, 루트테라피 스킨케어 브랜드, 더레미디 THE REMEDY ♩, [online], (2015.02.23. 공개)* * |
| 뷰티코리아뉴스,‘마유부터 해삼까지’화장품 신소재 찾기 열풍, [online], (2015.02.11. 공개)* * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20180042541A (en) * | 2016-10-18 | 2018-04-26 | 주식회사 코리아나화장품 | Cosmetic composition comprising the very high-pressure extract of narcissus tazetta bulb fermentation |
| CN107137315A (en) * | 2017-05-25 | 2017-09-08 | 甘肃青黛中草药美容研究有限责任公司 | It is a kind of that there are the skin care item for nourishing Shu Min effects by active component of fresh lily bulb extract |
| KR20200012487A (en) * | 2018-07-27 | 2020-02-05 | 제주대학교 산학협력단 | Cosmetic composition containing Narcissus extract |
| WO2021249960A1 (en) | 2020-06-09 | 2021-12-16 | Clariant International Ltd | Compositions comprising narcissus spp. plant extract and use thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| KR102189330B1 (en) | 2020-12-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102309958B1 (en) | A cosmetic composition for skin improvement comprising bulb extract | |
| JP7309620B2 (en) | Use of an extract of pericarp of NEPHELIUM LAPPACEUM for hydrating skin and/or mucous membranes | |
| KR20090056397A (en) | Composition for skin external application containing complex of herbal extracts | |
| KR102257342B1 (en) | Composition for antimicrobial and anti-inflammatory activities and manufacturing method thereof | |
| KR102189330B1 (en) | A cosmetic composition for skin improvement comprising bulb extract | |
| KR101020536B1 (en) | Moisturizing cosmetic composition containing extract of Sanguisorba officinalis and method of producing the same | |
| KR102300581B1 (en) | Compositions for improving skin conditions comprising plant extracts or fractions thereof | |
| KR102214985B1 (en) | Compositions for improving skin conditions comprising plant extracts or fractions thereof | |
| KR102248405B1 (en) | Cosmetic composition comprising extracts of davallia mariesii and extracts of chamaecyparis obtusa leaf for moisturizing the skin | |
| KR20120000251A (en) | A cosmetic composition comprising laminaria japonica | |
| KR102058294B1 (en) | Cosmetic composition for skin regenerating containing complex extracts of snail mucus, Boswellia serrata resin and Aloe barbadensis leaf, and cream comprising the same | |
| KR102226179B1 (en) | Cosmetic Compositions for Anti-aging Comprising Extracts of Plants | |
| KR20150086922A (en) | Composition for relieving skin irritation and moisturizing skin containing natural fermented pine leaf extract | |
| KR100887294B1 (en) | Cosmetic compositions containing hollyhock extracts | |
| KR101481208B1 (en) | Composition for skin external application comprising cryptotanshinone as the active ingredient | |
| KR102248406B1 (en) | Cosmetic composition comprising extracts of davallia mariesii, extracts of chamaecyparis obtusa leaf and extracts of zanthoxylum piperitum fruit for moisturizing the skin | |
| KR102459024B1 (en) | Cosmetic composition comprising mixed extract of verbena hybrida voss, cyclamen persicum mill. and saintpaulia ionantha h. wendl. for moisturizing the skin | |
| KR102162377B1 (en) | Extracts derived from natural products and cosmetic composition containing the same, and process for producing the same | |
| KR101415993B1 (en) | Composition for skin external application comprising Astragalus Membranaceus extract prepared by using pottery extractor | |
| KR101648466B1 (en) | Cosmetic composition for improving skin | |
| KR101436819B1 (en) | Cosmetic composition for moisturing, soothing skin and improving acne | |
| KR102337357B1 (en) | Cosmetic composition for skin regenerating containing Panax Ginseng root extract, Madecassoside, Oenothera Biennis seed oil and Carthamus Tinctorius seed oil | |
| JP3987733B2 (en) | Fibroblast activator and skin external preparation containing the same | |
| JP2023539314A (en) | Milk thistle oil to strengthen skin barrier function | |
| KR20220001161A (en) | Composition for skin protection, including extracts derived from natural products |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| E701 | Decision to grant or registration of patent right | ||
| A107 | Divisional application of patent | ||
| GRNT | Written decision to grant |